US Appeals Court Upholds Decision Removing FDA Authority Over Premium Cigars

In a significant win for the premium cigar industry, the United States Court of Appeals for the District of Columbia has upheld the decision to remove the FDA’s regulatory authority over premium cigars. The court’s unanimous ruling declared the FDA’s previous regulatory approach “fundamentally flawed,” citing serious deficiencies in the final rule.

The lawsuit, funded largely by 10 family-owned cigar companies through Cigar Rights of America (CRA), challenged the FDA’s authority to regulate premium cigars. Companies involved included Arturo Fuente, Ashton, J.C. Newman, La Flor Dominicana, My Father, Oliva, Padrón, Rocky Patel, Tatuaje, and Alec Bradley (which transitioned from family ownership in 2023).

The court’s decision reaffirms the earlier removal of FDA oversight while remanding the case to clarify the definition of “premium cigars.” However, the issue of retroactive user fees remains unresolved. Importantly, the ruling acknowledges the FDA’s ability to revisit the rule-making process, leaving open the possibility of future regulation.

Mike Copperman, Executive Director of CRA, expressed cautious optimism, stating:
“We are encouraged by the court’s acknowledgment that the FDA’s previous approach to regulating premium cigars was fundamentally flawed. This decision underscores the critical need for a clear and appropriate federal definition of premium cigars to ensure future regulations accurately reflect their unique characteristics.”

While the ruling marks a victory for the industry, it is not the end of the regulatory battle. The CRA is analysing the implications of the decision and remains committed to advocating for a fair framework that recognises the distinct nature of premium cigars.

Further updates on this evolving situation will be shared as the industry prepares for potential next steps. For now, premium cigar manufacturers, retailers, and enthusiasts can celebrate this favourable ruling.